Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy

Conditions

Autosomal Dominant Polycystic Kidney Disease

What is the purpose of this trial?

Currently the only approved use for rapamycin (sirolimus) is for immunosuppression after renal transplantation.

This trial is designed to determine whether rapamycin is safe and effective treatment for patients with polycystic kidney disease (ADPKD). Patients will be followed by volumetric magnetic resonance imaging (MRI) to observe for change in kidney (and cyst) size. Blood and urine samples will also be collected to evaluate for change in biomarkers with treatment.



Participation Guidelines

Age:
18 Years - 70 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Yale University
Dates:
June 2009
Last Updated:
March 7, 2014
Study HIC#:
0903004934

Clinicaltrials.gov ID: NCT00920309